GleamWall
中文EN

ANVS Annovis Bio, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1477845 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-107.9%
TTM EPS YoY-8.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-455.9%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets340.5%
Debt / equity—
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.08x
Accruals ratio36.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-09-302026Q2*2026-06-302026Q12026-03-312025Q4*2025-12-312025Q3*2025-09-302025Q2*2025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$0$0$0$0$0
R&D expense$15.78M$12.01M$16.72M$8.75M$6.29M$5.16M$5.01M$5.00M
SG&A expense$1.19M$2.37M$1.29M$955,151$1.14M$1.11M$1.27M$1.74M
Operating income-$16.97M-$14.38M-$18.01M-$9.71M-$7.43M-$6.27M-$6.28M-$6.73M
Income tax$0$0$0$0$0$0$0—
Net income-$9.46M-$14.82M-$17.61M-$9.83M-$7.26M-$6.22M-$5.54M-$5.86M
EPS (basic)-0.22-0.40-0.63—-0.37-0.32-0.32—
EPS (diluted)-0.22-0.40-0.63—-0.37-0.32-0.32—
Weighted avg. shares (diluted)42.63M37.52M27.85M—19.69M19.49M17.43M—
Balance sheet
Cash & equivalents$2.82M$18.73M$14.22M$19.53M$15.29M$17.13M$22.24M$10.55M
Total assets$5.50M$22.04M$16.24M$21.08M$17.19M$21.45M$26.74M$13.93M
Current liabilities$6.26M$6.36M$12.79M$3.64M$3.73M$2.81M$2.50M$3.88M
Total liabilities$18.74M$26.29M$13.12M$4.23M$4.03M$3.12M$2.68M$4.62M
Shareholders' equity-$13.23M-$4.25M$3.13M$16.85M$13.16M$18.33M$24.05M$9.31M
Shares outstanding42.69M42.61M28.54M27.20M20.19M19.49M19.49M14.14M
Cash flow statement
Operating cash flow-$16.04M-$21.91M-$9.01M-$8.93M-$3.49M-$5.11M-$8.10M-$8.29M
Financing cash flow$127,827$26.42M$3.70M$13.17M$1.64M$0$19.78M$6.20M
Stock-based compensation$355,102$1.61M$182,823$356,524$444,647$496,618$499,887$1.48M

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.